Combined brain stimulation and yoga for improving cognition in psychosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study explores whether anodal tDCS paired with a yoga program can enhance cognitive function, symptoms, and quality of life in people with psychosis. It will compare active tDCS, sham tDCS, and yoga as part of the intervention strategy. Neurophysiological changes will be examined to understand how the combined approach may produce effects. Participants are adults with psychosis who meet specific diagnostic and consent criteria and have limited prior exposure to mind-body practices. The Hong Kong Polytechnic University serves as the lead site for this research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) aged 18 to 65 years
* (2) diagnosis based on SCID for schizophrenia and related disorders, psychosis, and delusional disorder with the positive symptom measured by CGI ≤ 3
* (3) ability to understand the nature of the study and to give informed consent (The MacArthur Competence Assessment Tool for Clinical Research score ≥ 35)
* (4) Chinese-speaking
* (5) fewer than 10 hours of yoga and other mind-body intervention (e.g., Tai Chi, Qigong, Mindfulness) in the previous 3 months.

Exclusion Criteria:

* (1) Severe physical diseases, such as myocardial infarction, uncontrollable severe hypertension, fracture, severe spinal problems, or contraindication for exercise
* (2) comorbid substance dependence and seizure disorders
* (3) pregnancy or other contraindication to fNIRS
* (4) known history of intellectual disability or special school attendance, brain trauma, or organic brain disease
* (5) Individuals taking Benzodiazepine will still be recruited in the project, and will be excluded from the fNIRS measure.

Where it's running

• The Hong Kong Polytechnic University
  Hung Hom, Kowloon, Hong Kong Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Recovery-oriented suicide prevention for young people at clinical high risk for psychosis

  This program tests a peer-supported, clinician-led suicide prevention group for young people at clinical high risk for psychosis to see if it helps reduce suicidal thoughts and support recovery.

  Recruiting at 2 sites University of California, San Diego · Los Angeles, California and 1 other locations · NCT07756567

• See if an early-detection program reduces time to treatment for first-episode psychosis

  We test whether a large, region-wide early-detection program can shorten the time from first psychotic symptoms to treatment and help people function better later.

  Recruiting at 2 sites Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Copenhagen, Denmark and 1 other locations · NCT07716969

• Selenium supplementation for people with heart failure

  This trial will test whether taking a daily selenium supplement helps people with heart failure avoid hospitalization and reduce the risk of death.

  Recruiting at 11 sites Phase 3 Skane University Hospital · Oslo and 10 other locations · NCT07543562

• Cerebellar imaging markers to predict antipsychotic response in first-episode psychosis

  This will test whether cerebellar brain scans can predict how people with first-episode psychosis respond to 12 weeks of treatment with risperidone or aripiprazole.

  Recruiting Phase 4 Northwell Health · Glen Oaks, New York · NCT07483294

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.